Galalae Razvan, Tharavichitkul Ekkasit, Wanwilairat Somsak, Chitapanarux Imjai, Kimmig Bernhard, Dunst Jürgen, Lorvidhaya Vicharn
Medical Faculty, Christian-Albrechts-University Kiel, Germany ; Radiotherapy Department, Evangelical Clinics Gelsenkirchen, Germany.
Radiotherapy Department, Chiang Mai University, Thailand.
J Contemp Brachytherapy. 2015 Feb;7(1):86-92. doi: 10.5114/jcb.2015.49444. Epub 2015 Mar 5.
Starting in 1999, the University Cooperation Platform (UCP) implemented an exchange program of researchers and clinicians/physicists between the Christian-Albrechts-University Kiel in Germany and Chiang Mai University in Thailand, to initiate a sustainable base for long-term development of image-guided brachytherapy and in general for high-technology radiotherapy in Chiang Mai. A series of UCP protocols, based constructively on each other, were performed and evaluated at intermediate term follow-up. The first protocol, addressing computed tomography (CT)-optimized brachytherapy for advanced cervical cancer (n = 17), showed a significant reduction of D2cc for the bladder and sigmoid (p < 0.001) while maintaining a very high dose in D90 high-risk clinical target volume (HR-CTV) in comparison with standard point-based planning. In addition, after a follow-up of 19 months no tumor relapse was observed. The second UCP protocol, testing the impact of magnetic resonance imaging (MRI) guidance (n = 15) in patients with cervical cancer, proved significantly smaller D2cc doses for the bladder, rectum, and sigmoid (p = 0.003, p = 0.015, and p = 0.012), and secured highly curative mean doses in D90 HR-CTV of 99.2 Gy. The acute and late toxicity was excellent without any observed grade 3 or higher morbidity. In the third protocol, the combination of image-guided brachytherapy (IGBT) and whole pelvis intensity-modulated external beam radiotherapy (WP-IMRT) (n = 15) reaffirmed the significant reduction of D2cc doses for the bladder, rectum, and sigmoid (p = 0.001 or p < 0.001) along with high equivalent dose at 2 Gy (EQD2) in the HR-CTV, and demonstrated very low acute therapy-related toxicity in absence of grade 3 morbidity. The implementation of transabdominal ultrasound (TAUS) was the focus of the fourth UCP project aiming a more generous potential use of image-guidance on long-term, and enhancing the quality of soft tissue assessment complementary to conventionally planned gynecological brachytherapy. Analyses in 29 patients revealed significantly reduced OARs doses in bladder with a total EQD2 > 80 Gy for bladder in only 17.2% versus 62.1% in conventional planning, and in rectum EQD2 > 75 Gy in 44.8% versus 79.3%, respectively. In conclusion, analyses revealed excellent results for the high-dose-rate IGBT in patients with advanced gynecological cancer both by using CT and MRI, and/or the combination with WP-IMRT. They also define MRI as gold standard for soft tissue assessment and to determine more accurately HR-CTV. The use of TAUS-guidance adds quality aspects to the "classical" conventional X-ray based planning, especially in terms of real-time measures and adequate soft tissue information, and may lower significantly the dose in OARs. The review of all UCP-results reconfirms the importance of the established program that will continue to operate with subsequent projects.
从1999年开始,大学合作平台(UCP)实施了一项德国基尔基督教-阿尔布雷希茨大学与泰国清迈大学之间的研究人员与临床医生/物理学家交流计划,为清迈图像引导近距离放射治疗以及一般高科技放射治疗的长期发展建立一个可持续的基础。一系列相互建设性依存的UCP方案在中期随访时进行并评估。第一个方案针对晚期宫颈癌的计算机断层扫描(CT)优化近距离放射治疗(n = 17),与基于标准点的计划相比,膀胱和乙状结肠的D2cc显著降低(p < 0.001),同时在高危临床靶区(HR-CTV)的D90中保持非常高的剂量。此外,随访19个月后未观察到肿瘤复发。第二个UCP方案测试了磁共振成像(MRI)引导对宫颈癌患者的影响(n = 15),结果表明膀胱、直肠和乙状结肠的D2cc剂量显著更小(p = 0.003、p = 0.015和p = 0.012),并确保HR-CTV的D90平均治愈剂量为99.2 Gy。急性和晚期毒性良好,未观察到任何3级或更高等级的发病率。在第三个方案中,图像引导近距离放射治疗(IGBT)与全盆腔调强外照射放疗(WP-IMRT)联合应用(n = 15)再次证实膀胱、直肠和乙状结肠的D2cc剂量显著降低(p = 0.001或p < 0.001),同时HR-CTV中2 Gy时的等效剂量较高(EQD2),并且在无3级发病率的情况下显示出极低的急性治疗相关毒性。经腹超声(TAUS)的应用是第四个UCP项目的重点,旨在长期更广泛地潜在使用图像引导,并提高与传统计划的妇科近距离放射治疗互补的软组织评估质量。对29例患者的分析显示,膀胱的危及器官剂量显著降低,膀胱总EQD2 > 80 Gy的患者仅为17.2%,而传统计划中为62.1%,直肠EQD2 > 75 Gy的患者分别为44.8%和79.3%。总之,分析显示,无论是使用CT和MRI,和/或与WP-IMRT联合应用,高剂量率IGBT在晚期妇科癌症患者中都取得了优异的结果。它们还将MRI定义为软组织评估和更准确确定HR-CTV的金标准。TAUS引导的应用为基于“经典”传统X射线的计划增加了质量方面的内容,特别是在实时测量和足够的软组织信息方面,并且可能显著降低危及器官的剂量。对所有UCP结果的回顾再次证实了既定计划的重要性,该计划将继续与后续项目一起运作。